Introduction {#sec1}
============

One of the characteristics of the autonomic nervous system is the waxing and waning of its activity, both afferent and efferent. Similarly, the last 50 years have witnessed the waxing and waning of its interest for clinical cardiologists dealing with cardiac arrhythmias, sudden death, and heart failure.

Especially in the 1970s, but also later, much effort was devoted to the study of neural activity through the recording of single fibers in the sympathetic and vagal nerves ([@ref82], [@ref81]; [@ref64]; [@ref31]), which allowed the description of important autonomic reflexes ([@ref127]). In the 1970s, 1980s, and 1990s, interest for the autonomic nervous system peaked. Some investigators focused on the stimulation of nerves directed to the heart trying to derive information for potential clinical translation ([@ref119]), others focused on various aspects of the analysis of heart rate, either at rest ([@ref62]) or in response to stimuli ([@ref22]); these analyses of tonic or reflex autonomic activity had post-myocardial infarction (post-MI) and heart failure risk stratification as one significant objective ([@ref125]; [@ref87]; [@ref65], [@ref68]). During the last 20 years, there was a surge of interest for the possibility of modulating autonomic activity, especially the vagal one, also in chronic conditions such as heart failure ([@ref123], [@ref124]; [@ref38]); however, the combination of unsatisfactory results and superficial analyses ([@ref56]; [@ref51]) has somewhat cooled down these hopes. One area where clinical success has fueled interest is the one related to the prevention of life-threatening events by cardiac sympathetic denervation ([@ref120]).

Here, the three of us, who have collaborated in a number of studies, present our unabashed views on some of these topics.

Initial Overview {#sec2}
================

The neural control of the heart is accomplished throughout a multilevel neural network within the central nervous system and peripheral extracardiac and cardiac ganglia that exert their influence *via* the sympathetic and parasympathetic nervous systems ([@ref71]; [@ref142]). Cardiac diseases may profoundly affect central and peripheral mechanisms of neural control of cardiac function, thus resulting in maladaptive responses that may be critically involved in the progression of the disease or in the development of arrhythmias. Neural sensory information from the heart ([@ref95]; [@ref127]), blood vessels, and other organs is processed at different levels within the neuraxis with a first level of integration represented by the intrinsic cardiac nervous system located in the cardiac ganglia within the heart. The intrinsic cardiac nervous system processes sensory information and provides efferent input to the myocardium under the tonic modulation of the extrinsic sympathetic and parasympathetic input. Arterial baroreceptors play a paramount role in the neural control of the cardiovascular system ([@ref47]). Arterial baroreceptors are stretch receptors embedded in the adventitia of the carotid sinus and aortic wall. Increases in arterial blood pressure will result in an increased rate of impulse firing to the nucleus tractus solitarius, which modulates sympathetic and parasympathetic output to the cardiovascular system. The baroreflex control of circulatory homeostasis occurs on a negative feedback basis. Thus, the attending reflex decrease in sympathetic activity and increase in vagal activity will reduce heart rate, cardiac contractility, and peripheral resistance. Opposite changes are associated with an arterial pressure decrease.

By complex interactions between the main neurotransmitters \[namely, noradrenaline, acetylcholine, and neuropeptide Y; ([@ref44])\] and their effects on specific receptors of cardiac cells in the sinoatrial node, atrioventricular node, and left ventricle, the autonomic nervous system affects several aspects of cardiac electrophysiology. At the sinus node level, efferent vagal activity decreases while sympathetic activity increases the spontaneous depolarization rate of sinus node cells.

Furthermore, it has been known for many years that sympathetic nervous system stimulation may be pro-arrhythmic, particularly in conditions of acute myocardial ischemia ([@ref54]; [@ref136]; [@ref500]; [@ref139]), while vagal nerve stimulation may reduce the potential for lethal arrhythmias ([@ref61]; [@ref152]). Thus, by controlling the autonomic traffic to the heart, the baroreceptors are involved in the susceptibility to ventricular and supraventricular arrhythmias. Moreover, by controlling the hemodynamic adjustments to blood pressure changes, they also play a role in the clinical response to sustained rhythm disorders ([@ref40]; [@ref70]).

Damage to cardiac sensory nerve endings caused by acute myocardial infarction and left ventricular remodeling directly affects the baroreceptor system. The attending reflex autonomic dysfunction, characterized by reduced parasympathetic and increased sympathetic activity coupled with neural remodeling and nerve sprouting ([@ref30]), promotes arrhythmogenesis.

The prominent neurohumoral mechanism at play in heart failure is the sympathetic nervous system whose increased activity coupled with vagal withdrawal is initiated by the arterial baroreflex ([@ref55]). Although other mediators, including sympatho-excitatory reflexes, humoral factors, and central mechanisms ([@ref49]) contribute to the development of sympathetic-parasympathetic imbalance in heart failure, an impairment of baroreflex control of heart rate is a prominent characteristic of the heart failure syndrome and a reliable marker of the severity of the disease ([@ref87]).

Relevant insights into the pathophysiological implications of heart disease-related baroreflex impairment date back to the early 1970s when it was recognized that baroreceptor reflexes can be modulated by cardiac afferent sympathetic activity activated by mechanical and chemical stimuli ([@ref81]; [@ref127]). An animal model provided the first evidence that reduction in cardiac parasympathetic control is associated with an increased risk for sudden death. In this canine model ([@ref23]; [@ref122]), baroreflex sensitivity (BRS) was impaired by myocardial infarction, with the greatest impairment noted in animals particularly susceptible to sudden death ([@ref138]). Similarly in humans, a tight relationship between reduced baroreceptor activity and heart disease state was first reported by [@ref46] and was subsequently found to be associated with an increased risk of cardiac mortality and sudden cardiac death in post-MI and heart failure patients ([@ref87]; [@ref65], [@ref67]).

The initial results with BRS led some investigators to consider the possibility that powerful baroreceptive reflex would imply that the attendant increase in vagal activity to the sinus node would extend to the ventricles as well. The high specificity of the cardiac innervation ([@ref94]; [@ref116]), the central organization of cardiovascular reflexes ([@ref156]), and the important report by [@ref58] indicate clearly that such an extrapolation would be both naïve and unwarranted. Indeed, a heart-rate response indicative of increased vagal activity does not exclude the possibility of a dominant sympathetic activity at ventricular level (e.g., the diving reflex, hypoxia, and inferior myocardial ischemia). Nonetheless, the most frequent reflex response is synergistic, i.e., one limb of the autonomic nervous system is excited with simultaneous inhibition of the other ([@ref156]), and the reduction in heart rate produced by the baroreflex is accompanied by a reflex withdrawal of sympathetic activity that is generalized and extends to the ventricles. In the sudden death animal model that played such an important role in the development of the clinical interest for BRS ([@ref122]), the dogs with higher BRS were also those with larger heart rate reductions during acute myocardial ischemia despite continuation of exercise ([@ref122]). One logical implication is that the animals responding with strong vagal reflexes to blood pressure increases are likely to respond similarly to acute myocardial ischemia. The animals with the greatest sinus node response to the baroreflex test are less prone to sudden death during myocardial ischemia, and conversely, those with the most reduced BRS are more vulnerable to ventricular fibrillation. This does not mean that the baroreflex test predicts the autonomic changes at the ventricular level during myocardial ischemia but indicates that it can often predict the outcome during an ischemic episode, which is what really matters. Although, as correctly stated ([@ref58]), the use of spontaneous or reflex changes in heart rate as an indicator of what might happen at the ventricular level would certainly be naive, their use to identify individuals at varying risk of life-threatening events is a rational exploitation of the current understanding of cardiovascular pathophysiology.

Assessment of Cardiac Autonomic Function {#sec3}
========================================

As the baroreflex affects the balance between parasympathetic inhibition and sympathetic excitation of the sinoatrial node of the heart, sinus node activity (either spontaneous or in response to a provocation) can provide information on the underlying regulatory system.

Assessment of Arterial Baroreflex Control {#sec4}
-----------------------------------------

Several methods have been developed so far to evaluate arterial baroreflex control in humans ([@ref69]; [@ref102]). The reference method in clinical and research applications entails the assessment of the heart rate response to a physiological provocation ([@ref143]; [@ref69]). In the original method, intravenous injections of small boluses of phenylephrine are used to raise blood pressure transiently, and the resultant reflex bradycardia (expressed as the following heart periods) is used as an index of BRS. A wealth of non-invasive indicators of the arterial-cardiac baroreceptor reflex sensitivity can be obtained by the joint analysis of beat-to-beat spontaneous fluctuations of systolic blood pressure and RR interval series ([@ref69]). These methods include: model-free techniques ([@ref117]; [@ref101]), interactions among heart period and systolic arterial pressure ([@ref109]; [@ref90]; [@ref84]), models searching for specific patterns of baroreflex origin ([@ref20]) or heart rate responses to systolic pressure changes ([@ref11]), and others merely requiring a certain degree of association between spontaneous heart period and systolic arterial pressure variations ([@ref155]). Some methods lead to an indirect estimate of BRS *via* analysis of the bi-phasic response of the sinus node to a premature ventricular contraction (named heart rate turbulence) that is largely dependent on the baroreflex ([@ref118]; [@ref66]). Despite indices of baroreflex control derived from spontaneous variability cannot be considered fully equivalent to the interventional ones ([@ref42]), their value in clinical setting has been proved ([@ref69]; [@ref102]). The reliability of these non-invasive indices has been recently reviewed ([@ref100]) with special attention to their predictive value ([@ref102]).

Assessment of Heart Rate Variability {#sec5}
------------------------------------

Since the seminal study by [@ref1], autonomic function has been non-invasively inferred from the variability of sinus RR interval obtained from surface electrocardiogram (ECG). The disappearance of RR variability after vagal blockade by high dose atropine not only proved the predominance of vagal over sympathetic cardiac modulation in humans at rest ([@ref104]; [@ref85]) but also confirmed that RR interval variability was related to autonomic control. Indeed, in humans at rest, the primacy of the vagal versus the sympathetic drive leads to a heart rate lower than the intrinsic heart rate of the isolated heart ([@ref59]).

The RR mean provides an indication of the tonic balance between sympathetic and vagal mean neural activities ([@ref80]), while the magnitude of the RR variations about its mean is linked to the balance of the spontaneous variations of vagal and sympathetic neural activities about their correspondent means, usually referred to as vagal and sympathetic modulations ([@ref146]; [@ref93]; [@ref9]; [@ref79]). A number of techniques have been developed to quantify the RR interval variability in order to evaluate cardiac autonomic regulation. The measurement of RR interval variability was initially based on simple statistics, such as the standard deviation of RR interval variation and its derivative, and on power spectral analysis that separates and quantifies the various oscillations that exist in the RR interval signal. At variance with the conventional measures of RR interval variability, complexity markers and fractal measures of HRV account for the inherent irregularity, long range correlation, and scale invariance of the spontaneous fluctuations of RR interval ([@ref52]; [@ref111]).

It has been recently stressed that RR variability markers might be biased proxies of autonomic modulation as a result of the nonlinear relation between mean RR and magnitude of RR changes ([@ref92]; [@ref26]; [@ref79]). The rate-dependency of RR variability markers is the consequence of the direct effect of acetylcholine concentration on the diastolic depolarization rate of the sinus node pacemaker cells producing larger variations of the cycle length if the cycle length is longer ([@ref160]). This relation might limit the value of RR variability markers expressed in absolute units because an augmented modulation of the autonomic activity increases RR variability indices but a greater fluctuations of RR might be simply a consequence of bradycardia, regardless of whether it is of autonomic origin or due to modifications of the properties of sinus node pacemaker cells \[e.g., I~f~ modifications; [@ref160]; [@ref37]; [@ref26]\]. Since this effect is the mere consequence of the sinus node transduction process, it could affect any marker based on RR changes including BRS. Therefore, the possibility of interpreting RR variability markers as proxies of autonomic modulation is fully preserved as long as the compared populations and/or experimental conditions exhibit the same RR mean. Alternatively, it was suggested to use RR variability indices that feature an intrinsic normalization ([@ref160]; [@ref37]). Among those indices, normalized high frequency (HF) powers and the low frequency (LF)/HF ratio can be exploited ([@ref93]). Especially whether the RR mean varies among groups and experimental conditions and, thus, the genuine role of an altered neural modulation is not warranted, it is recommended to check for the potential variations of the LF/HF ratio before concluding that RR variability indices expressed in absolute units indicate modifications of the autonomic control.

Concurrent Assessment of RR and QT Variability {#sec6}
----------------------------------------------

The difficulty in the assessment of the sympathetic modulation from RR variability is a direct consequence of the vagal nature of the spontaneous fluctuations of RR ([@ref45]), especially when the magnitude of the RR changes is assessed in absolute units ([@ref86]). This observation, in association with the clinical importance of the non-invasive inference of cardiac sympathetic modulation, has led to search for possible alternatives, still obtained from the ECG, to the sole analysis of RR variability.

An important one, in our opinion, is the study of the QT interval variability ([@ref78]; [@ref18]; [@ref15]). Its interest lies in the fact that the amplitude of the QT changes has been related to the magnitude of sympathetic control. Indeed, the higher the sympathetic drive and its variations about its mean value such as during an orthostatic challenge, mental stress, or advanced age, the greater the magnitude of the QT variations in healthy individuals ([@ref89]; [@ref107], [@ref114], [@ref105]; [@ref157]; [@ref96], [@ref97]; [@ref24]; [@ref15]; [@ref48]). This link holds even in pathological conditions characterized by a high sympathetic drive ([@ref19]; [@ref158]; [@ref5]; [@ref14], [@ref16]) and provides new clues for stratifying the risk of arrhythmic events ([@ref3]; [@ref98]; [@ref140]; [@ref32]; [@ref43]; [@ref91]; [@ref147]; [@ref112]).

These observations suggested a possible strategy to separately quantify vagal and sympathetic modulations in humans *via* the concomitant analysis of RR and QT variabilities ([@ref112]). Vagal modulation is inferred from the respiratory sinus arrhythmia, namely the portion of the RR variability in the HF (from 0.15 to 0.5 Hz) band ([@ref57]; [@ref104]). Sympathetic modulation is inferred from the power of the QT variability in the LF (from 0.04 to 0.15 Hz) band ([@ref105]; [@ref15]). This choice is more robust than the mere exploitation of the QT variance because it prevents the bias produced by non-autonomic influences such as cardiac axis movements leading to periodical artifacts which would affect the QT measurement at the respiratory rate ([@ref75]; [@ref108]). The interpretation of QT variability markers is made more complex by the QT-RR relation ([@ref17]), which mirrors on the surface ECG the adaptation of action potential duration to the cycle length observed at the cellular level ([@ref34]), and by the influences of the autonomic nervous system on the QT-RR relation ([@ref161]; [@ref107]; [@ref76]). Modeling approaches can describe the dynamic dependence of QT on previous RR variations ([@ref161]; [@ref107], [@ref114]) and even account for confounding factors such as respiration ([@ref106]). Alternative approaches excluding the influences of cardiac neural control directed to the sinus node on the regulation of the QT dynamics and preventing the need of hypothesizing any *a priori* defined, and arbitrary, QT-RR relation ([@ref115]) are based on gating the QT variability analysis at similar RR mean ([@ref29]) or on the normalization of QT variability markers to the magnitude of RR changes ([@ref19]; [@ref15]).

Complexity of the Cardiac Autonomic Control {#sec7}
-------------------------------------------

Complexity analysis is an additional approach for the assessment of cardiac control with an inherent normalization given that it is fully independent of the amplitude of spontaneous RR and QT changes ([@ref99]; [@ref111]). Under normal conditions, the simultaneous action of multiple regulatory mechanisms operating with slightly different frequencies within the LF and HF bands produces irregular changes of RR and QT intervals. Disease and aging impair the sinus node responsiveness and decrease the level of irregularity of the RR and QT beat-to-beat dynamics ([@ref52]). Complexity analyses of RR and QT variabilities provide non-redundant information. Indeed, the larger irregularity of the QT variability compared to that of the RR variability points to the greater complexity of the neural control directed to the ventricles than that to the sinus node ([@ref58]; [@ref72]; [@ref13]; [@ref7]). The decreased complexity of the RR variability during vagal withdrawal and sympathetic activation induced by orthostatic challenge ([@ref113]; [@ref150]; [@ref12]) is interpreted as a consequence of the reduction of the respiratory sinus arrhythmia and of the increase of a dominant LF component limiting the spectral content of the RR variability series ([@ref110]). Therefore, complexity indices derived from RR variability are mainly under vagal control ([@ref110]). Indeed, low-pass filtering approach canceling respiratory sinus arrhythmia from the RR variability prevented the increase of RR variability complexity during nighttime and under β-blockers ([@ref7]). At difference with the complexity of RR variability, the complexity of the QT variability in healthy individuals during orthostatic challenge and in pathological populations featuring a dominant sympathetic drive remains high ([@ref12]; [@ref74]) or even increases ([@ref144]; [@ref88]; [@ref114]; [@ref73]) compared to basal condition or control subjects. Senescence in a healthy population is accompanied by an increase of QT variability complexity ([@ref24]). The dynamics of QT variability become more irregular during sympathetic activation due to the prevailing action of inputs driving QT independently of RR changes ([@ref114]). The decrease of the T-wave amplitude with sympathetic activation is likely to play a role in increasing the beat-to-beat irregularity of QT by making the process of delineation of the T-wave offset more difficult ([@ref15]). Therefore, the complexity of the QT variability could largely represent the sympathetic control directed to the ventricles, largely unrelated to the cardiac autonomic regulation impinging on the sinus node. We suggested that a limited complexity of the QT variability might be protective against arrhythmic risk ([@ref7],[@ref8]).

Risk Stratification {#sec8}
===================

Effective risk stratification for patients who might develop life-threatening ventricular arrhythmia and sudden cardiac death is one of the main unsolved areas in clinical cardiology. Arrhythmic risk represents the sum of several different risk-augmenting processes and factors. Understanding the relation between changes in autonomic activity and cardiac electrophysiological properties has led to the view that the autonomic nervous system modulates interactions between triggering factors and the underlying electrophysiologic substrate. This points to a significant potential prognostic value of markers of autonomic activity.

Since the 1990s, the analysis of BRS has been considered as a tool that might help identifying "high-risk" patients. A multicenter study on more than 1,200 post-infarction patients demonstrated the incremental prognostic value provided by an impaired BRS when combined to left ventricular ejection function and to the potential trigger of non-sustained ventricular tachycardia ([@ref65], [@ref67]). Specifically, a depressed BRS, a reduced left ventricular ejection fraction, and the presence of non-sustained ventricular tachycardia were all independent predictors of mortality, but depressed BRS almost doubled the risk of death provided by the other two markers. Moreover, among patients with either reduced or preserved left ventricular function but without signs of electrical instability, mortality differed significantly according to the presence or absence of preserved autonomic function ([@ref67]; [@ref41]).

The role of baroreflex-mediated responses in the control of hemodynamic stability is particularly relevant during the course of a sustained ventricular rhythm. Inadequate baroreflex-mediated sympatho-excitation during a sustained ventricular tachycardia in post-infarction patients was the leading cause of an unfavorable hemodynamic profile leading to circulatory collapse ([@ref70]).

Randomized trials, demonstrating that among post-infarction patients mortality can be effectively reduced by prophylactic implantation of a cardioverter defibrillator, established a paradigm shift in risk stratification through the assessment of left ventricular ejection fraction as the gold standard risk predictor. However, this does not deprive autonomic markers of their clinical value ([@ref154]). It is now clear that left ventricular ejection fraction measurement has both limited sensitivity and specificity as a tool for arrhythmic risk stratification and that the field of risk stratification should move from the "high-risk ejection fraction" to the broader concept of the "high-risk patients" ([@ref33]). This transition implies a novel opportunity for autonomic markers to be re-evaluated in their involvement in the pathogenesis of arrhythmic risk and incorporated in novel prediction models. Moreover, novel ECG-based risk markers that quantify sympathetic activity-associated repolarization instabilities are promising in their ability to guide decisions about the prophylactic implantation of a cardioverter defibrillator ([@ref10]). The markers tested by [@ref10] are framed in an emerging area of biomedical signal processing aiming at monitoring relevant electrocardiographic fiducial points and time intervals under the hypothesis such that their evolution over time might provide information about cardiac control.

In a founder population of long QT syndrome type 1 (LQT1), which avoids the confounding factors due to different mutations and segregates the malignant *KCNQ1*-A341V mutation ([@ref27]; [@ref36]; [@ref28]), the characterization of cardiac autonomic control and baroreflex function was found to be useful to improve the risk stratification of arrhythmic events ([@ref137]; [@ref35]; [@ref7],[@ref8], [@ref6]; [@ref112]). In this population which is at the highest risk of fatal events in situations of high sympathetic drive ([@ref129]), it was found that subjects who did not experience arrhythmic events, namely the asymptomatic mutation-carriers, have a completely different autonomic profile compared to those experiencing syncope or cardiac arrest requiring resuscitation. Indeed, asymptomatic individuals exhibited longer RR ([@ref137]), lower BRS ([@ref137]), higher QT variability in the LF band during daytime ([@ref112]), lower respiratory sinus arrhythmia during nighttime and under β-blockers ([@ref112]), slower heart rate recovery after exercise test ([@ref35]), and lower QT variability complexity ([@ref7],[@ref8], [@ref6]). These findings suggested that, besides RR lengthening, the combination of a more reactive sympathetic drive to the ventricles (i.e., adapting more rapidly QT to RR changes and limiting irregularity of QT changes during a sympathetic stressor) and of a sluggish vagal responsiveness after exercise represents a protective mechanism. Remarkably, non-mutation carriers belonging to the same family line ([@ref27]; [@ref28]) have an autonomic profile more similar to symptomatic patients than asymptomatic ones, thus suggesting that there are peculiar traits of the autonomic control that might be key for survival because they reduce the severity of the disease ([@ref137]; [@ref112]).

Neuromodulation {#sec9}
===============

Vagal Neuromodulation {#sec10}
---------------------

One relevant aspect of several abnormalities related to the baroreceptors and autonomic nervous system pathophysiology is that they are often correctable by treatment. While β-blockers are the mainstay in the management of autonomic imbalance, device technology and advances in neuromodulatory techniques paved the way to directly target the autonomic nervous system. Baroreflex activation therapy (BAT), providing chronic baroreflex activation through electrical stimulation of the carotid sinus, has been initially developed for the treatment of resistant hypertension. Clinical studies have underlined the potential of BAT to improve blood pressure control and reduce the need of anti-hypertensive therapy at cost of few side effects despite the invasiveness of the procedure ([@ref25]). BAT is currently being evaluated in heart failure with reduced ejection fraction. Initial studies support the hypothesis that baroreflex activation can add significant therapeutic benefit on top of guideline-directed medical therapy in patients with advanced heart failure. A randomized controlled trial (the BeAT-HF trial) is actively recruiting an estimated sample size of 480 patients with New York Heart Association functional class II heart failure but excluding patients actively receiving cardiac resynchronization therapy; its completion is expected by April 2021 ([@ref83]).

Experimental studies in an established conscious canine model of post-MI sudden cardiac death ([@ref122]) demonstrated that vagus nerve stimulation (VNS) was effective in preventing ventricular fibrillation induced by acute myocardial ischemia ([@ref152]). The initially promising translation of animal studies to the clinical setting of patients with HF and reduced ejection fraction ([@ref123]; [@ref38]) did not show consistent results in randomized trials ([@ref159]; [@ref51]). In the debate following these studies, several critical issues (patient selection, proper titration of VNS therapy, effective markers for therapy, and pattern of vagal fibers stimulation) have been identified that would require further assessment.

Transcutaneous electrical stimulation of the auricular branch of the vagus nerve located at the tragus, which is effective in stimulating afferent vagal nerve fibers, has been suggested to represent an alternative access path to the same neuronal network without invasiveness and common side effects including hoarseness, sore throat, shortness of breath, and coughing, even though it is likely to lead to a smaller release of ACh compared to direct vagal efferent stimulation. In a study based on spontaneous variability, in young healthy subjects, transcutaneous VNS acutely reduced resting heart rate and the response to orthostatic stress ([@ref148]). Transcutaneous VNS is being studied for a number of pathological conditions including ventricular arrhythmias, heart failure, and myocardial infarction. Experimental and clinical data recently suggested that chronic intermittent VNS lasting 2 h/day for 2 months reduced inducibility of ventricular arrhythmias ([@ref162]).

Sympathetic Neuromodulation {#sec11}
---------------------------

The fact that acute myocardial ischemia is often associated with life-threatening arrhythmias was recognized from the early days ([@ref54]). When it was shown that acute myocardial ischemia also elicits a powerful excitatory sympathetic reflex within seconds ([@ref82]), thus increasing the release of norepinephrine at the ventricular level, the link was established. One obvious consequence was the rationale for the use of β-adrenergic blocking agents to prevent cardiac arrhythmias in ischemic heart disease. Another consequence was the concept that if arrhythmias are triggered by an abrupt release of norepinephrine, the section of the nerves mediating this release might have had a protective effect ([@ref120]).

Given the quantitative dominance of the left sided cardiac sympathetic nerves at the ventricular level, the interest went immediately to the potential effects of left cardiac sympathetic denervation (LCSD). Thus, a series of experiments, mostly performed in the 1970s, provided the necessary information. It was shown that LCSD prevents arrhythmias associated with acute myocardial ischemia in normal hearts ([@ref135]) and in hearts with a healed myocardial infarction ([@ref133]), that it does not impair cardiovascular performance during exercise ([@ref132]), that it does increase the capability of the coronary bed to dilate ([@ref131]), and that it does not cause denervation supersensitivity ([@ref134]). However, the most important effect in terms of clinical relevance is the increase produced by LCSD on the threshold for ventricular fibrillation ([@ref130]). This makes it less likely that a heart will fibrillate and, together with the overall reduction in the norepinephrine release, constitutes the primary rationale for the use of LCSD in several conditions in which the risk for ventricular fibrillation is high.

The evidence for a powerful antifibrillatory effect of LCSD is now firmly established ([@ref120]) and has been observed at clinical level in three different sets of patients: post-MI patients at high risk for sudden death ([@ref126]), long QT syndrome patients ([@ref128]), and patients with catecholamine polymorphic ventricular tachycardia (CPVT) syndrome ([@ref39]). Whenever there is a recurrence after LCSD, which is not common for LQTS and CPVT patients, it is reasonable to perform right cardiac sympathetic denervation as well, as we started to do in the 1990s ([@ref501], [@ref129]). There are growing data suggesting that bilateral cardiac sympathetic denervation can be useful in patients with recurrent ventricular tachycardia related to either ischemic heart disease or dilated cardiomyopathy ([@ref153]). Different views exist on the timing for ablating the right cardiac sympathetic nerves; namely, whether together with the left or just in case of failure of unilateral left cardiac sympathetic denervation. Our view is to follow the time-honored precepts of medicine which suggest to begin by the lowest effective dose and to increase it whenever this fails. An implication is that for a number of patients, unilateral left cardiac sympathetic denervation will be sufficient ([@ref120]).

Overall, it is now clear that cardiac sympathetic denervation can save lives while preserving adequate quality of life ([@ref2]; [@ref121]) and that there is not always the need to rush toward an implantable cardioverter defibrillator.

Renal Denervation {#sec12}
=================

Renal sympathetic nerve activity plays a crucial role in the control of cardiovascular homeostasis and is involved not only in the pathogenesis of hypertension but also in other cardiovascular processes such as heart failure, and perhaps cardiac arrhythmias. Renal afferent and efferent nerves function in a reflex loop where afferent input from the kidney to the central nervous system is integrated with inputs from other neural reflexes to determine the level of sympathetic outflow to individual organs. Renal denervation (RDN) as a method of modulating sympathetic activity by interrupting afferent and efferent sympathetic nerve signaling appears to be an attractive therapeutic target in patients with cardiovascular disease triggered by sympathetic overactivity such as hypertension, heart failure, and -- according to some -- even atrial or ventricular arrhythmias. RDN has been initially introduced to reduce blood pressure in subjects with resistant hypertension ([@ref77]). While initial clinical trial results failed to reach a consensus on the efficacy of RDN in this context ([@ref21]), three subsequent sham-controlled studies that were carefully designed and rigorously conducted have shown that RDN significantly reduces blood pressure regardless of the use of antihypertensive drugs ([@ref149]; [@ref4]; [@ref60]). Notably, the use of multi-electrode catheter and more ablations per artery have definitely improved the RDN procedure in the more recent studies that also took into account the distribution of the sympathetic nerves among the renal arteries.

Clinical implications of RDN are well beyond blood pressure control. Interestingly, a recent meta-analysis including 17 studies revealed that RDN improved a number of cardiovascular markers of organ damage including left ventricular mass index, central augmentation index, and carotid-femoral pulse wave velocity independent of blood pressure ([@ref63]). Moreover, several clinical RDN studies report beneficial effects on ventricular and supraventricular arrhythmias ([@ref151]; [@ref103]). In the recently reported ERADICATE-AF trial that randomized 302 patients with paroxysmal atrial fibrillation and hypertension, RDN added to catheter ablation, compared with catheter ablation alone, significantly increased the likelihood of freedom from atrial fibrillation at 12 months ([@ref145]). While we report these studies and their claims, we cannot help expressing a certain degree of skepticism on the rationale by which RD should provide protection against life-threatening cardiac arrhythmias. The underlying concept seems to be that reduction or elimination of renal afferent would decrease the efferent sympathetic activity directed to the heart, which is mediated by the stellate ganglia. We find it difficult to conceive how this "reduction" could be greater than that produced by the direct section of these nerves, as it is produced by the cardiac sympathetic denervation performed by removing the lower half of the stellate ganglion/ganglia with the first four thoracic ganglia.

RDN has been reported to exert beneficial effects on cardiac function and remodeling in animal models of heart failure ([@ref141]), but the results in patients are largely inconsistent due in part to limited power with small sample sizes. In a meta-analysis including two controlled (80 patients) and two uncontrolled studies (21 patients) ([@ref50]), 6 months after RDN, there was a greater increase in left ventricular ejection fraction and a greater decrease in left ventricular end-diastolic diameter in the RDN group than in the control group. No serious adverse events such as acute renal artery stenosis and dissection occurred.

Conclusions {#sec13}
===========

A paper like this one does not really need a traditional conclusion, which would merely be a pale summary of what has been a serious effort to share with the interested reader our experience and our views. Our hope is that more and more young investigators will be attracted by this fascinating field of research, which is endowed with so many areas of clinical relevance.
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